SINOMED's HT Supreme? DES Gains Further International Safety Recognition
Recently, at the WorldLink Forum: Best Global Research in PCI, Professor Alexandra J. Lansky from Yale School of Medicine announced the five-year follow-up results of the PIONEER-III clinical trial conducted in the United States, Japan, and Europe for SINOMED's new class of healing-targeted drug eluting stent HT Supreme™. Compared to the DP-DES, the HT Supreme™ demonstrated “numerical benefit” in both safety and efficacy metrics. This achievement not only enhances SINOMED's core competitiveness in the global market but also signifies another milestone for Chinese medical device in gaining international recognition. Moving forward, the PIONEER-III research team will conduct more detailed data analysis and research on the performance of the HT Supreme™ DES on specific patient groups. Relevant research findings will be released timely.
Established in the Tianjin Economic-Technological Development Area in 2007, SINOMED has set up subsidiaries in Beijing, Suzhou, and Hong Kong in China, and also in the United States, Japan, and France. In October 2019, SINOMED was listed on the Shanghai Stock Exchange as a Sci-Tech Innovation Board enterprise. It has established an internationally competitive R&D, production, and operation system, focusing on the key fields of the interventional treatment of cardiovascular, cerebrovascular, and structural heart diseases. Over 1.9 million pieces of the company's main products, including coronary drug-eluting stent, coronary balloon dilation catheter, and rapid exchange intercranial balloon catheter, have been used in more than 3,000 hospitals, benefiting hundreds of thousands of patients in China, Southeast Asia, and South America.
First, please LoginComment After ~